Anti-FAAH1 Monoclonal Antibody for WB, IF/ICC, ELISA - O00519

Core Product Specifications and Parameters

Biological Background: FAAH1 Function and Localization

• FAAH1 catalyzes the hydrolysis of bioactive fatty acid amides such as the sleep-inducing oleamide and the endocannabinoid anandamide, preferentially hydrolyzing polyunsaturated substrates, thus terminating their signaling. Related references: PMID:17015445, PMID:19926788, PMID:9122178
• It also hydrolyzes 2-arachidonoylglycerol (2-AG), another endocannabinoid. Related references: PMID:21049984
• In cooperation with PM20D1, FAAH hydrolyzes intracellular N-fatty acyl amino acids, acting as a physiological regulator of these molecules (By similarity).
• Subcellularly, FAAH1 is associated with the endomembrane system, cytoplasm, and cytoskeleton.
• It is highly expressed in the brain, small intestine, pancreas, skeletal muscle, and testis, with lower expression in kidney, liver, lung, placenta, and prostate.
• Phosphorylation and direct protein sequencing evidence indicate post-translational regulation; it localizes to membrane via a transmembrane helix.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 480–579 of human FAAH1; design experiments considering that the antibody may recognize epitopes within this C-terminal region.
• For WB, expect a band at approximately 63 kDa. Use appropriate loading controls and validate the specificity in your sample type.
• For IF/ICC, optimize fixation and permeabilization protocols for endomembrane/cytosolic targets; consider using suitable organelle markers.
• Cross-reactivity with mouse and rat has been reported; verify detection in the relevant model systems prior to routine use.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic manufacturers and laboratories with one-stop access to validated IVD raw materials, including monoclonal antibodies for endocannabinoid and lipid signaling research. Our portfolio includes optimized anti-FAAH1 clones, validated antibody pairs, bulk ancillary reagents, and custom sourcing for rare targets, streamlining assay development from concept to clinic.